LTFS
ARGS

Ladenburg Thalmann Financial Services’s Argos Therapeutics, Inc. ARGS Stock Holding History

Ladenburg Thalmann Financial Services’s Portfolio ARGS Stock Details ARGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-128
Closed – – 5616
2018
Q2 		$0 Hold
128
– – ﹤0.01% 5247
2018
Q1 		$0 Hold
128
– – ﹤0.01% 5385
2017
Q4 		$0 Sell
128
-75
-37% -$252 ﹤0.01% 5301
2017
Q3 		$1K Hold
203
– – ﹤0.01% 4908
2017
Q2 		$1K Hold
203
– – ﹤0.01% 4849
2017
Q1 		$2K Buy
203
+140
+222% +$8.86K ﹤0.01% 4657
2016
Q4 		$6K Hold
63
– – ﹤0.01% 4196
2016
Q3 		$6K Hold
63
– – ﹤0.01% 4123
2016
Q2 		$7K Buy
63
+28
+80% +$3.74K ﹤0.01% 4010
2016
Q1 		$4K Buy
+35
New +$2.83K ﹤0.01% 4234

Other funds holding ARGS

PI
Pharmstandard International Luxembourg $29M AUM 3.25% 1-Year Est. Return

Ladenburg Thalmann Financial Services's ARGS Position: Q3 2018 in Review

Ladenburg Thalmann Financial Services sold out of Argos Therapeutics, Inc. (ARGS) in Q3 2018, closing a stake of 128 shares.

Ladenburg Thalmann Financial Services first reported a position in ARGS in Q1 2016 and held it in 10 quarters. The position peaked at $7K in Q2 2016. 1 fund tracked by Wall St. Rank holds ARGS as of Q3 2018.

  • Ladenburg Thalmann Financial Services reported no remaining Argos Therapeutics, Inc. position as of Q3 2018 after selling out during the quarter.
  • Ladenburg Thalmann Financial Services sold 128 Argos Therapeutics, Inc. shares in Q3 2018.
  • Ladenburg Thalmann Financial Services first reported a position in Argos Therapeutics, Inc. in Q1 2016 and held it in 10 quarters.
  • Ladenburg Thalmann Financial Services's Argos Therapeutics, Inc. position peaked at $7K in Q2 2016.
  • 1 fund tracked by Wall St. Rank held Argos Therapeutics, Inc. as of Q3 2018.

Based on Ladenburg Thalmann Financial Services's 13F filing for Q3 2018, filed 14 Nov 2018.